NASDAQ:ACHL Achilles Therapeutics (ACHL) Stock Price, News & Analysis $1.05 +0.01 (+0.48%) (As of 04:25 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Achilles Therapeutics Stock (NASDAQ:ACHL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Achilles Therapeutics alerts:Sign Up Key Stats Today's Range$1.03▼$1.0550-Day Range$0.70▼$1.0552-Week Range$0.63▼$1.76Volume33,183 shsAverage Volume463,471 shsMarket Capitalization$43.14 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company OverviewAchilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Achilles Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks40th Percentile Overall ScoreACHL MarketRank™: Achilles Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 696th out of 974 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAchilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageAchilles Therapeutics has received no research coverage in the past 90 days.Read more about Achilles Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Achilles Therapeutics are expected to decrease in the coming year, from ($1.70) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achilles Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achilles Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchilles Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Achilles Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.55% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently decreased by 40.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAchilles Therapeutics does not currently pay a dividend.Dividend GrowthAchilles Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.55% of the float of Achilles Therapeutics has been sold short.Short Interest Ratio / Days to CoverAchilles Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achilles Therapeutics has recently decreased by 40.63%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 1 people have added Achilles Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.38% of the stock of Achilles Therapeutics is held by insiders.Percentage Held by Institutions56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Achilles Therapeutics' insider trading history. Receive ACHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHL Stock News HeadlinesEuropean Equities Traded in the US as American Depositary Receipts Edge Higher in Monday TradingSeptember 24, 2024 | msn.comAchilles Therapeutics PLC: Achilles Therapeutics Announces Strategic UpdateSeptember 19, 2024 | finanznachrichten.deTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 8, 2024 | Colonial Metals (Ad)Achilles Therapeutics to Lay Off Staff as Part of Review, Discontinues Drug TrialsSeptember 19, 2024 | marketwatch.comAchilles Therapeutics ADRs Rise 32% on Cost-Cutting MeasuresSeptember 19, 2024 | marketwatch.comAchilles Therapeutics Discontinues TIL-based CNeT ProgramSeptember 19, 2024 | markets.businessinsider.comAchilles climbs after decision to find strategic alternativesSeptember 19, 2024 | msn.comAchilles Therapeutics Shares Are Trading Higher: What You Need To KnowSeptember 19, 2024 | msn.comSee More Headlines ACHL Stock Analysis - Frequently Asked Questions How have ACHL shares performed this year? Achilles Therapeutics' stock was trading at $0.8890 at the beginning of the year. Since then, ACHL shares have increased by 17.0% and is now trading at $1.04. View the best growth stocks for 2024 here. How were Achilles Therapeutics' earnings last quarter? Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.41) EPS for the quarter, meeting analysts' consensus estimates of ($0.41). When did Achilles Therapeutics IPO? Achilles Therapeutics (ACHL) raised $176 million in an initial public offering (IPO) on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO. Who are Achilles Therapeutics' major shareholders? Top institutional investors of Achilles Therapeutics include BML Capital Management LLC (9.98%). How do I buy shares of Achilles Therapeutics? Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Achilles Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achilles Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), Aquestive Therapeutics (AQST), CRISPR Therapeutics (CRSP), ChargePoint (CHPT) and NVIDIA (NVDA). Company Calendar Last Earnings8/14/2024Today11/08/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACHL CUSIPN/A CIK1830749 Webwww.achillestx.com Phone44-0-20-8154-4600FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$2.00 Potential Upside/Downside+281.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.24% Return on Assets-41.69% Debt Debt-to-Equity RatioN/A Current Ratio8.24 Quick Ratio8.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.30Miscellaneous Outstanding Shares41,090,000Free Float38,877,000Market Cap$43.14 million OptionableNot Optionable Beta1.35 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:ACHL) was last updated on 11/8/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThis is treasonIf you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.